CN102170779A - 抗微生物泡沫组合物,制品和方法 - Google Patents
抗微生物泡沫组合物,制品和方法 Download PDFInfo
- Publication number
- CN102170779A CN102170779A CN2009801390191A CN200980139019A CN102170779A CN 102170779 A CN102170779 A CN 102170779A CN 2009801390191 A CN2009801390191 A CN 2009801390191A CN 200980139019 A CN200980139019 A CN 200980139019A CN 102170779 A CN102170779 A CN 102170779A
- Authority
- CN
- China
- Prior art keywords
- foam
- goods
- antimicrobial
- wound
- froth bed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006260 foam Substances 0.000 title claims abstract description 105
- 230000000845 anti-microbial effect Effects 0.000 title claims description 63
- 239000000203 mixture Substances 0.000 title description 20
- 238000000034 method Methods 0.000 title description 13
- 239000004599 antimicrobial Substances 0.000 claims abstract description 26
- 241000894006 Bacteria Species 0.000 claims abstract description 8
- 229920002413 Polyhexanide Polymers 0.000 claims abstract description 7
- 239000011324 bead Substances 0.000 claims description 20
- 230000008961 swelling Effects 0.000 claims description 15
- -1 Cationic quaternary ammonium compound Chemical class 0.000 claims description 10
- 229920000289 Polyquaternium Polymers 0.000 claims description 10
- 230000005540 biological transmission Effects 0.000 claims description 8
- 238000006116 polymerization reaction Methods 0.000 claims description 7
- 229920000615 alginic acid Polymers 0.000 claims description 6
- 235000010443 alginic acid Nutrition 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 229920005830 Polyurethane Foam Polymers 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 239000011496 polyurethane foam Substances 0.000 claims description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 3
- 229940123208 Biguanide Drugs 0.000 claims description 3
- 150000004283 biguanides Chemical class 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 3
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920000098 polyolefin Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 239000011148 porous material Substances 0.000 abstract description 7
- 239000011159 matrix material Substances 0.000 abstract description 5
- 230000001464 adherent effect Effects 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 55
- 208000027418 Wounds and injury Diseases 0.000 description 55
- 239000000463 material Substances 0.000 description 37
- 239000012530 fluid Substances 0.000 description 31
- 239000003795 chemical substances by application Substances 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 10
- 210000000416 exudates and transudate Anatomy 0.000 description 10
- 239000000835 fiber Substances 0.000 description 10
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Chemical compound CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000005416 organic matter Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 206010000269 abscess Diseases 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000005660 chlorination reaction Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000002077 nanosphere Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 239000002313 adhesive film Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 238000009954 braiding Methods 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- YIOJGTBNHQAVBO-UHFFFAOYSA-N dimethyl-bis(prop-2-enyl)azanium Chemical compound C=CC[N+](C)(C)CC=C YIOJGTBNHQAVBO-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 230000002879 macerating effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000002102 nanobead Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000003357 wound healing promoting agent Substances 0.000 description 2
- IWYNVAJACBPVLT-UHFFFAOYSA-N 1-[10-(4-amino-2-methylquinolin-1-ium-1-yl)decyl]-2-methylquinolin-1-ium-4-amine;diacetate Chemical compound CC([O-])=O.CC([O-])=O.C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 IWYNVAJACBPVLT-UHFFFAOYSA-N 0.000 description 1
- WFENCVFYUBXRSH-UHFFFAOYSA-N 1-dodecyl-2-methylquinolin-1-ium-4-amine;acetate Chemical compound CC([O-])=O.C1=CC=C2[N+](CCCCCCCCCCCC)=C(C)C=C(N)C2=C1 WFENCVFYUBXRSH-UHFFFAOYSA-N 0.000 description 1
- AOAQBXAGGBSALU-UHFFFAOYSA-N 2-[2-[dodecanoyl(methyl)amino]ethyl-dimethylazaniumyl]-n-phenylethanimidate;hydrochloride Chemical compound [Cl-].CCCCCCCCCCCC(=O)N(C)CC[N+](C)(C)CC(=O)NC1=CC=CC=C1 AOAQBXAGGBSALU-UHFFFAOYSA-N 0.000 description 1
- KUXUALPOSMRJSW-IFWQJVLJSA-N 2-[6-[[amino-[[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 KUXUALPOSMRJSW-IFWQJVLJSA-N 0.000 description 1
- CBYAPCMTYUIARL-UHFFFAOYSA-N 4-phenylbut-3-en-1-amine Chemical compound NCCC=CC1=CC=CC=C1 CBYAPCMTYUIARL-UHFFFAOYSA-N 0.000 description 1
- GQCIBLGQUDFKGX-WLHGVMLRSA-M 5-amino-2-[(e)-2-(4-amino-2-sulfophenyl)ethenyl]benzenesulfonate;(2,4-dichlorophenoxy)methyl-dimethyl-octylazanium Chemical compound CCCCCCCC[N+](C)(C)COC1=CC=C(Cl)C=C1Cl.OS(=O)(=O)C1=CC(N)=CC=C1\C=C\C1=CC=C(N)C=C1S([O-])(=O)=O GQCIBLGQUDFKGX-WLHGVMLRSA-M 0.000 description 1
- JMTNOKRGERWNME-UHFFFAOYSA-L 6-[dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]hexyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium;dichloride Chemical compound [Cl-].[Cl-].CC1CCCC(C)(C)C1CCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCC1C(C)CCCC1(C)C JMTNOKRGERWNME-UHFFFAOYSA-L 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108050004290 Cecropin Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JGFDZZLUDWMUQH-UHFFFAOYSA-N Didecyldimethylammonium Chemical compound CCCCCCCCCC[N+](C)(C)CCCCCCCCCC JGFDZZLUDWMUQH-UHFFFAOYSA-N 0.000 description 1
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108060003100 Magainin Proteins 0.000 description 1
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- QDYLMAYUEZBUFO-UHFFFAOYSA-N cetalkonium chloride Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 QDYLMAYUEZBUFO-UHFFFAOYSA-N 0.000 description 1
- 229960000228 cetalkonium chloride Drugs 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229950007585 chlorphenoctium amsonate Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000007766 curtain coating Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 229960001378 dequalinium chloride Drugs 0.000 description 1
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940078672 didecyldimethylammonium Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 229950011018 dofamium chloride Drugs 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000012992 electron transfer agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950004179 laurolinium acetate Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960002285 methylbenzethonium chloride Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108010062940 pexiganan Proteins 0.000 description 1
- KGZGFSNZWHMDGZ-KAYYGGFYSA-N pexiganan Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 KGZGFSNZWHMDGZ-KAYYGGFYSA-N 0.000 description 1
- 229950001731 pexiganan Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000005365 phosphate glass Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002553 poly(2-methacrylolyloxyethyltrimethylammonium chloride) polymer Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/34—Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/0091—Plasters containing means with disinfecting or anaesthetics means, e.g. anti-mycrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/206—Biguanides, e.g. chlorohexidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/208—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Dispersion Chemistry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
可形成包括下述的制品:至少一层泡沫层,泡沫层和与泡沫层组合的至少一种抗微生物剂,该抗微生物剂包括PHMB,PEHMB,或其衍生物,置于至少一部分泡沫层上的至少一层不粘附层,不粘附层可透湿气;和置于泡沫层的至少另一部分上的膜,该膜可透气,以允许湿气逃逸,但对细菌基本上不可渗透。另一制品可包括至少一层泡沫层,该泡沫包括不同大小的孔,至少一些孔至少部分被至少一种可洗脱的抗微生物剂填充,不同大小的孔与泡沫层一起形成梯度。再一制品可包括泡沫基体和与泡沫基体一起布置的多种可溶解部件,与可溶解部件一起组合的至少一种抗微生物剂,以便当其溶解时,抗微生物剂被洗脱且在泡沫基体内产生孔或孔隙。还公开了由上述制品形成的伤口敷料。
Description
发明领域
本发明涉及抗微生物泡沫组合物,制品和方法。
发明背景
在其中提到或讨论文献、学位论文或知识信息(item of knowledge)的本说明书中,这一种提到或讨论不是承认该文献、学位论文或知识信息或其任何结合在优先权日时,公众可获知,公众公知,是普通技术知识的一部分,或者在其他情况下,根据合适的法律规定,构成现有技术;或者已知与尝试解决本说明书所涉及的任何问题有关。
提出了各种抗微生物组合物,制品和方法。然而,这种伤口组合物和方法具有各种缺陷和缺点。
例如,美国专利No.5465735公开了伤口敷料,它包括夹在第一和第二外部片材材料之间的接收并保留伤口流体的吸收垫,其中放置在伤口上的第一片材材料是穿孔的非粘附膜,用以防止敷料粘附到伤口上,第二片材材料的特征在于细菌不可渗透,吸收垫是多层结构,所述多层结构包括低密度吸收剂材料的里层,用以接收从伤口扩散到敷料上的流体,和高密度吸收剂材料的上覆层用以接收并保留通过里层扩散的伤口流体,以便抑制因与伤口相邻的吸收垫表面区域润湿导致的皮肤浸软。
然而,本领域仍需要在减少和/或防止形成不想要的微生物有机物方面的有效性增加,安全并提供伤口护理控制效率改进的组合物、装置和方法。
尽管讨论了常规技术的一些方面有助于理解本发明的公开内容,但申请人决不否认这些技术方面,且认为要求保护的发明可包括此处讨论的一个或更多个常规技术性方面。
定义
除非另有说明,此处所使用的术语“微生物有机物”或“微生物”用于指代微小的有机物,其中包括真菌,细菌和/或病毒有机物。因此,此处所使用的术语“抗微生物剂”是指杀灭或在其他情况下抑制这种真菌、细菌和/或病毒有机物生长的组合物或试剂。
发明概述
本发明可解决以上讨论的现有技术中的一个或更多个问题和缺陷。然而,认为本发明被证明可用于解决其他问题和缺陷,或者在许多技术领域中提供优势和优点。因此,要求保护的发明不应当必然解释为限制到解决此处讨论的任何特定问题或缺陷上。
本发明可任选地具有一个或更多个以下的特征、优势或优点:具有抗微生物性能的吸收泡沫,其中伤口渗出物保持在远离伤口和皮肤的腔室内,从而防止皮肤浸软和细菌在伤口内扩散;便于改进伤口接触和流体管理的螺旋切割泡沫;具有孔度梯度有助于试剂控制释放到伤口内的泡沫材料;具有孔度梯度的泡沫材料,其中包括最初传输相对大量试剂,接着随着时间流逝传输降低量试剂的至少一种试剂;具有孔度梯度的泡沫材料,其中包括最初传输相对小量试剂,接着随着时间流逝传输较大量试剂的至少一种试剂;具有孔度梯度的泡沫材料,以便较小的孔与材料面向伤口的一侧邻近,和相对较大的孔隙位于进一步远离面向伤口一侧的材料内;具有孔度梯度的泡沫材料,以便较大的孔与材料面向伤口的一侧邻近,和相对较小的孔隙位于进一步远离面向伤口一侧的材料内;孔度微调的泡沫材料,以便相对高水平的渗出物的存在将促使传输相对大量的试剂到伤口上;和孔度微调的泡沫材料,以便相对低水平的渗出物的存在将促使传输相对小量的试剂到伤口上;含有抗微生物剂且包埋在泡沫内的大小变化的可溶解珠粒,所述可溶解珠粒不仅充当抗微生物剂的载体和传输基体,而且由于珠粒大小和/或浓度梯度变化导致视需要在不同时间处传输不同浓度的抗微生物剂;包埋在泡沫内的可溶解珠粒,所述可溶解珠粒使敷料具有按需的吸收能力;控制pH到6-7范围内的略酸性水平,以降低伤口感染的几率。
根据一个替代的方面,本发明提供一种制品,它包括:至少一层泡沫层,和与泡沫层结合的至少一种抗微生物剂,该抗微生物剂包括PHMB,PEHMB,或其衍生物,置于至少一部分泡沫层上的至少一层不粘附层,不粘附层可透湿气;和置于泡沫层的至少另一部分上的膜,该膜可透气,以允许湿气逃逸,但对细菌基本上不可渗透。
根据进一步的方面,本发明提供一种制品,它包括至少一层泡沫层,该泡沫包括不同大小的孔,至少一些孔至少部分被至少一种可洗脱的抗微生物剂填充,不同大小的孔在泡沫层形成梯度。
根据再一方面,本发明提供一种制品,它包括泡沫基体和与泡沫基体一起布置的多种可溶解部件,与可溶解部件一起结合的至少一种抗微生物剂,以便当其溶解时,抗微生物剂被洗脱且在泡沫基体内产生孔或缝隙。
附图简述
图1是根据本发明形成的制品,组合物,层压体或敷料的截面示意图。
图2是图1中的制品、组合物、层压体或敷料的一个替代方面的底视图。
图3是根据本发明的一个实施方案构造的泡沫材料的截面示意图。
图4是根据本发明一个替代实施方案构造的泡沫材料的截面示意图。
图5是根据本发明进一步的替代实施方案形成的制品、组合物、层压体或敷料的截面示意图。
图6是根据本发明一个任选的实施方案构造的具有孔度的泡沫材料的截面示意图。
图7是根据本发明的替代实施方案构造的具有孔度的泡沫材料的截面示意图。
图8是根据本发明额外的实施方案的含泡沫的制品、组合物、层压体或敷料的截面示意图。
详细说明
本发明的抗微生物的组合物和制品,例如层压体或伤口敷料可含有合适的抗微生物剂。可使用任何合适的抗微生物剂或试剂的组合,例如单独或组合的聚合的双胍(例如,聚六亚甲基双胍(PHMB))和/或聚亚乙基六亚甲基双胍(PEHMB)和/或离子金属。
根据进一步的非限定性实例,合适的抗微生物剂包括单独或组合的一些金属或化合物,其中包括这些金属,例如银、金、铜或锌可用作抗微生物剂。另外认为抗微生物剂处理可以是许多试剂的组合,例如银、PHMB、CHG、EDTA或其他合适的抗微生物剂,以便实现协同效应。
根据一些实施方案,抗微生物剂可包括阳离子表面活性剂或阳离子季铵化合物。这些化合物的非限定性实例包括:氯化苄烷铵,氯化苄乙铵;溴化十四烷基三甲基铵;氯化十六烷基吡啶;安索氯芬铵;醋酸克菌定;地喹氯铵;溴化度米芬;醋酸氨月甲喹;氯化甲苄乙氧铵;氯甲十四烷基吡啶;ortaphnum chloride;创必龙;西他氯铵;氯化杜法铵;溴化四乙铵;氯化二癸基二甲铵;溴化四乙铵;氯化二甲基二烯丙基铵;对三烷基氨乙基苯乙烯单体;和三烷基(对乙烯基苄基)氯化铵。
根据进一步的实施方案,抗微生物剂可包括阳离子表面活性剂或聚合的季铵化合物。这些化合物的非限定性实例包括:聚(氯化二烯丙基二甲铵);聚(3-氯-2-羟丙基)甲基丙烯酰氧基乙基二甲基氯化铵;聚(丙烯酰胺-甲基丙烯酰氧基乙基三甲基溴化铵);聚(丙烯酸丁酯-甲基丙烯酰氧基乙基三甲基溴化铵);聚(1-甲基-4-乙烯基溴化吡啶);聚(1-甲基-2-乙烯基溴化吡啶);和聚(甲基丙烯酰氧基乙基三乙基溴化铵)。
根据额外的替代实施方案,抗微生物剂可包括聚季铵盐(polyquaternium)。聚季铵盐是强调在聚合物内存在季铵中心而使用的新字。聚季铵盐荷正电,一些具有抗微生物性能。目前存在至少37种聚季铵盐牌号的不同的已知聚合物。定期地鉴定新的聚季铵盐。不同的聚合物的通过在措辞“聚季铵盐”之后紧跟的数值来鉴别。因此,本发明考虑可能使用任何目前已知的聚季铵盐-1到聚季铵盐-37的物质,以及目前没有牌号,落在以上所述的宽的定义或分类内的将来的聚季铵盐。
根据进一步的实施方案,抗微生物剂可包括阳离子抗微生物肽,例如e-聚-1-赖氨酸,爪蟾抗菌肽,蛾血素,皮抑菌肽,培西加南,艾塞加南,Oniganan和防卫素。
根据额外的替代方案,抗微生物剂可包括两性表面活性剂,例如包括烷基甜菜碱,十二烷基甜菜碱,椰油两性氨基乙酸盐(cocoamphoglycinate)和椰油酰胺基丙基甜菜碱。
根据进一步的实施方案,抗微生物剂可包括溴基化合物,例如聚(4-乙烯基-N-烷基溴化吡啶);和聚(4-乙烯基-N-己基溴化吡啶)。
本发明的制品、组合物、层压体或敷料可包括与至少一种材料,例如泡沫结合的一种或更多种以上所述的抗微生物剂。可使用任何合适的泡沫。非限定性实例包括聚氨酯泡沫,或生物材料类泡沫,例如藻酸盐(酯)泡沫,透明质酸泡沫,生物玻璃泡沫,或胶原泡沫。
图1-2中示出了具有抗微生物性能且使湿气远离患者皮肤防止浸软的吸收剂制品或伤口敷料的实施方案。正如此处所示的,层压体或敷料10包括用任何合适的抗微生物剂或试剂的组合,例如以上所述的那些材料处理过的泡沫12。
可将抗微生物剂以液体形式引入到泡沫12内,其中所述抗微生物剂可以是泡沫共混物的含水部分的一部分,在烘箱干燥之前,喷洒到“未加工”的泡沫表面上,通过或者喷洒或者浸染(padding)技术施加到干燥的泡沫表面上,或者可将抗微生物剂以粉末形式引入到泡沫12内,其中在混合头处引入该粉末或者在干燥之前喷淋到未加工的泡沫表面上。
根据进一步的替代实施方案,可包装泡沫以供在含有一种或更多种抗微生物剂和任选具有治疗价值的额外的其他化合物的液体或凝胶中浸泡使用。这一液体或凝胶将与泡沫结合,产生有利地针对伤口愈合和/或抗微生物防护而构造的制品。
也可施加薄膜形式的抗微生物剂。可任选地通过伤口流体量,pH,离子强度,有机物质,或者赋形剂或活性成分在薄膜内的溶解度,控制抗微生物剂的溶解。可存在多层薄膜。
由任何合适的材料,例如或其他合适的非粘附膜(例如聚烯烃,聚酯,聚氨酯或EVA)制造的非粘附层14与伤口表面接触。非粘附层14具有允许伤口流体流入到泡沫12内,但隔离湿气与皮肤以防止浸软的孔16。可进一步构造孔16,以便湿气可仅仅在远离伤口的一个方向上传输。另外,可根据待除去的伤口流体的粘度,调节孔16的直径(0.010-0.125``)。孔径可以是随机的,其组合提供可变的流体传输吸收性能。也可在敷料的一个区域内选择具有较大孔和在另一区域内具有较小孔的孔图案,以控制流体处理性能并最小化相邻的皮肤浸软。如图1所示,非粘附层14绕泡沫12的边缘包裹,保持渗出物在由此形成的腔室内,与伤口和皮肤相隔离。根据一个潜在的替代实施方案,可使用多孔膜层(例如,由Tredegar Corporation,Richmond,Virginia制造的那些)替代非粘附层14,以隔离伤口流体与皮肤。
层压体或敷料10可进一步任选地包括由任何合适材料形成的顶膜(top film)18,所述顶膜10可用任何合适的粘合剂20涂布,以确保将敷料固定到皮肤上。用粘合剂背衬的顶膜18可透气,允许湿气从皮肤中逃逸,但对细菌基本上不可渗透,防止污染。合适的湿气渗透率(MVTR)范围可以是300-3000gm/m2/天。
根据进一步的任选实施方案,泡沫12可包括不同密度12a,12b的泡沫的多层,以最佳方式导引流体吸收,如图3所示。在不同密度12a,12b的泡沫层之间的每一界面处,可***含有活性成分和/或抗微生物剂的膜22(或多层膜22a,22b)。可通过膜的组成与物理性能控制抗微生物剂的溶解行为。一个实例是使用经皮或经粘膜递送体系,例如可溶解的膜技术。另一实例是可溶解的珠粒一体化为膜形式。
或者,除了将抗微生物剂掺入到泡沫12内以外,还可将抗微生物剂掺入到非粘附层14的层内,或者用其替代泡沫12。根据进一步的替代实施方案,可用合适的抗微生物剂或抗微生物剂的组合涂布非粘附层14,任选地程序设计其性能,以在层压体或敷料10的预期寿命内传递有效程度的抗微生物性能。
另外,认为泡沫也可用指示溶液处理,所述指示溶液在抗微生物剂存在下保持无色,但当抗微生物剂洗脱出敷料时,颜色变化,以指明其中抗微生物剂被耗尽的那些区域。
如图5所示,根据本发明进一步的实施方案,以上提及的抗微生物泡沫12可提供有位于中心的螺旋割纹(cuts)24。该割纹24的构造使得允许泡沫差别溶胀。这些割纹24可例如允许泡沫12的伤口覆盖部分朝伤口溶胀而不是引起泡沫2翘曲和“倾斜(tent)”。这一特征因此可提供较好的流体控制和患者护理。
还认为泡沫结构12可含有就速度和溶胀比来说,溶胀性能不同的层(例如,12a,12b;图3)。可设计这一差别溶胀,引起泡沫翘曲和“倾斜”。可使用任何合适的机构促进所需的溶胀行为。在T.Mora等人,“Buckling of Swelling Gels”,Eur.Phys.J.E 20,119-124(2006)中公开了一种这样的技术,其全部内容在此通过参考引入。
另外,可使用外部施加的真空,周期性泵送出保持伤口流体的吸收剂容器,以便在吸收剂容器填充之后可再利用它。
根据进一步的任选的实施方案,本发明可包括泡沫组合物,层压体或敷料,其中泡沫的主体呈现基本上不同孔度的梯度。任选地构造孔度梯度,以有助于控制释放在其内包含的一种或更多种试剂,例如一种或更多种以上提及的合适的抗微生物剂。该试剂可以是一种或更多种抗微生物剂,疼痛管理剂,消炎药,清创剂,伤口愈合剂,血管生成因子,伤疤管理剂,或有益于伤口愈合的其他试剂或其任何组合。例如,可使用单一试剂,或不同类型的相同试剂的组合,或两种或更多种不同类型或试剂的组合。
如图6所示,可通过具有较大泡孔或孔隙140,实现材料面向伤口侧160具有孔度梯度120的泡沫材料100。可使用泡沫材料100,例如作为伤口敷料。该孔隙可含有一种或更多种抗微生物剂,并可能地与其他治疗剂组合。在泡沫材料100内,孔度进一步在远离面向伤口侧160减少(180,200)。可将浓度为约0.01%-2wt%的抗微生物剂掺入到泡沫内。在面向伤口侧的较大孔隙140(例如,约50-100微米)允许高含量的伤口流体流入到泡沫内,这本身可引起相应地相对高水平的抗微生物剂最初释放到伤口内。当引入更多的流体并进一步行进到敷料内时,通过改变泡孔或孔隙大小180(例如,约10-50微米),影响流体吸收曲线,和相应地对活性剂的释放曲线产生影响。当流体进一步向上行进到敷料内时,孔度200的额外变化(例如约1-10微米)将促进泡沫100中流体吸收和/或活性成分释放曲线的进一步变化。因此,例如,采用这一构造,最初可释放相对大量的抗微生物剂,且相应地相对大地吸收伤口渗出物,和随后释放相对小量的抗微生物剂,和相应地相对较少地吸收渗出物。
在本发明的另一方面中,可相对于图6所示的实施方案,逆转吸收和试剂释放曲线。因此,在图7所示的实施方案中,梯度120使得较小的泡孔或孔隙200朝向泡沫层材料100的接触伤口侧160定位,而在泡沫层材料100内进一步远离面向伤口的一侧160孔隙变得较大(180,140)。在面向伤口一侧160处较小的孔隙200(例如,约1-10微米)允许最初相对低含量的伤口流体进入到泡沫内,这反过来可引起最初在孔隙内包含的相应地相对低含量的抗微生物剂释放到伤口内。当引入更多的流体且进一步行进到敷料内时,通过改变泡孔或孔隙大小180(例如,约10-50微米),影响流体吸收曲线,且相应地对活性剂的释放曲线产生影响。当流体进一步行进到敷料内时,孔度140再进一步的变化(例如约50-100微米)将有助于泡沫100中流体吸收和/或活性成分释放曲线进一步变化。因此,例如采用这一构造,最初可释放相对小含量的抗微生物剂以及相应地相对小比例的伤口渗出物,和随后释放相对大量抗微生物剂,和相应地相对较大地吸收渗出物。
尽管以在单一泡沫层内提供的形式描述了以上所述的孔度梯度,但也可借助流延、挤出或合适的粘合剂体系,通过固定两个或更多个不同孔度和/或厚度的不同的固化泡沫,实现类似的构造。
如图8所示,根据本发明的进一步的方面,提供具有可溶解珠粒210(例如,磷酸盐玻璃,淀粉颗粒或其他)的材料200,将其掺入到泡沫基体220内。材料200适合于用作伤口敷料。珠粒210可封装任何合适的抗微生物剂,例如以上提及的那些,且也可含有一种或更多种此处公开的其他治疗剂,在图8中统称为元件212。可按照“可程序设计”顺序形式提供珠粒210。例如,更多的流体意味着更多的珠粒溶解并产生更多的开放空间以保持更多的流体,相反较少的流体引起较少的珠粒溶解,并进而产生较少的开放空间,从而对于最佳的潮湿的伤口愈合环境来说,有助于在伤口位点处维持理想的流体平衡。合适的珠粒顺序或分布的实例可包括较小尺寸珠粒的密度梯度,或者使用不同大小的珠粒,如图6-7所示。例如,当珠粒210溶解时,留下孔隙。随着时间流逝,这种孔隙可增加吸收度。因此,可选择溶解珠粒210的大小,及其在泡沫基体内的分布图案,以便随着时间流逝,增加或降低吸收度到所需的程度,正如上所述。珠粒210可以任选地以图案形式掺入到泡沫内,以当它吸收伤口渗出物时,控制层压体或敷料溶胀的方向和性质。
可通过任何合适的技术,形成以上所述的含有抗微生物剂的珠粒。例如,可混合抗微生物剂与超临界二氧化碳,然后在聚合或聚合物形成过程中,将这一混合物置于压力下。控制二氧化碳的剂量将控制聚合物的粘度。通过突然降低压力,二氧化碳膨胀,以在聚合物基体内形成抗微生物剂的纳米泡。
在本发明的再一实施方案中,在此处所述的控制释放的泡沫材料中,使用盐,例如氯化钠,和/或氯化钾和/或EDTA,在类似于图6或7所示或如上所述的泡沫基体内实现孔度梯度。通过控制在泡沫基体内盐晶体的大小,实现梯度。合适的大小可包括以上所述的孔度范围。可将活性剂仅仅以盐形式掺入到仅仅泡沫内,或者掺入到泡沫和盐二者内。当流体被吸收到泡沫基体内时,盐溶解,并留下开放的孔隙。在盐内活性剂的量,盐晶体的大小,和通过溶解的盐晶体留下的孔隙大小将控制并限定活性剂的释放曲线,以及通过留下的孔隙或空隙的吸收曲线。可利用盐的溶解度差别,实现孔隙变化的孔度或通道。例如,在伤口流体内使用具有低和高溶解度的盐的组合。高度可溶的盐将溶解,从而首先产生孔隙的网络,同时低溶解度的盐区域将保留原样或者缓慢地产生孔隙的网络。
在再一实施方案中,藻酸钠/钙用抗微生物剂和/或治疗剂处理且有策略地分布在泡沫结构内。可按照任何方式,例如此处阐述并描述的那些,可在泡沫基体内改变密度,和/或可在材料内改变颗粒的大小。当这些颗粒凝固(jell)和液化时,例如当与伤口渗出物接触时,在泡沫内产生孔隙。因此,根据该材料的一种任选的用途,此处所述类型的机理用于程序设计释放抗微生物剂和/或治疗剂,以及程序设计湿气转移远离伤口。
根据进一步任选的实施方案,可将PHMB包封的纳米纤维或球掺入到泡沫基体内。根据进一步的替代实施方案,不可溶解的纳米球,纳米颗粒,或珠粒可与可溶解的颗粒一起置于泡沫基体内,所述可溶解的颗粒当通过吸收的伤口流体溶解时可产生孔度。这些不可溶解的纳米球,纳米颗粒或珠粒可通过任何合适的机理,起到除去或抑制非所需的要素离开伤口流体的功能。合适的机理包括或者直接或者通过已经固定到纳米球、纳米颗粒或珠粒上的中间物质进行的选择性粘合技术。
根据进一步的实施方案,在泡沫形成的“未加工”未固化阶段中敷设(layer)不同孔度和/或性能的泡沫层。或者,也可通过合适的粘合剂体系,一起固定孔度和/或厚度不同的两种不同的固化泡沫。
根据进一步的实施方案,可溶解的藻酸盐(酯)或羧甲基纤维素纤维包括在泡沫、层压体或敷料内以控制溶胀。纤维可任选地方向性取向,以便在所需的方向上控制溶胀。例如,包埋的纤维在固化和干燥工艺之后变为牢固地固定到泡沫并成为泡沫的一部分。由于这种固定,因此在纤维水合过程中,纤维沿着纤维轴提供抗泡沫的移动。这些纤维的双轴或多轴取向提供平面内抗泡沫溶胀,从而助长与纤维所在平面垂直的溶胀。纤维可具有各种形式,例如,但不限于,编织或非编织结构或多种单独的连续纤维。
根据进一步的替代实施方案,控制伤口pH以便最佳地愈合的无毒的化学颗粒,例如碳酸氢钠、柠檬酸盐等包括在泡沫、层压体或敷料内。
伤口敷料当然可包括额外的活性成分或试剂,例如治疗剂、特殊感觉剂(organoleptic agent),生长因子,止痛药,组织支架剂、止血剂、蛋白质抑制剂,胶原,酶,抗血栓剂,***,消炎药,抗癌剂,血管舒张物质,伤口愈合剂,血管生成剂,血管抑制(angiostatic)剂,免疫促进剂,皮肤封闭剂,诱导定向细菌生长的试剂,赋予杀菌或抑菌活性的试剂,使微生物的新陈代谢作用和/或生物膜形成去稳定或破坏的电子转移试剂,其组合和类似物。可通过各种方式,例如电场或信号、温度、时间、压力、湿气、光(例如,紫外光)、超声能、超声、其组合和类似方式,触发活性试剂的释放。
表达在本说明书中所使用的各成分、组成、反应条件等等用量的任何数值应当理解为在所有情况下用术语“约”修饰。尽管列出了数值范围和参数,但此处列出的主题的宽范围是近似值,所列出的数值尽可能精确地表示。然而,任何数值可固有地包含一定的误差或不确定性,这根据它们各自的测量技术中发现的标准偏差看出。此处引证的特征无一应当解释为援引35U.S.C.§112,6,除非明确地使用术语“方式(means)”。
尽管结合本发明的优选实施方案描述了本发明,但本领域的技术人员要理解,可在没有脱离本发明的精神和范围的情况下,做出没有具体地描述的增加,删除,改性和替代。
Claims (20)
1.一种制品,它包括:
至少一层泡沫层,泡沫层和与泡沫层结合的至少一种抗微生物剂,该抗微生物剂包括PHMB,PEHMB,或其衍生物,
置于至少一部分泡沫层上的至少一层不粘附层,不粘附层可透湿气;和
置于泡沫层的至少另一部分上的膜,该膜可透气,允许湿气逃逸,但对细菌基本上不可渗透。
2.权利要求1的制品,其中该制品包括伤口敷料,该伤口敷料具有至少部分由所述不粘附膜形成的面向伤口的一面。
3.权利要求1的制品,进一步包括多层不同密度的泡沫层。
4.权利要求3的制品,其中在多层泡沫之间形成至少一个界面,且进一步包括置于界面处的含有至少一种抗微生物剂的至少一层。
5.权利要求1的制品,进一步包括与不粘附层结合的至少一种抗微生物剂。
6.权利要求1的制品,其中至少一层泡沫层进一步包括能在视觉上表明在泡沫层内不存在抗微生物剂的指示剂。
7.权利要求1的制品,其中泡沫包括聚氨酯泡沫,藻酸盐(酯)泡沫,透明质酸泡沫,生物玻璃泡沫,或胶原泡沫,和其中一层不粘附层包括聚烯烃,聚酯,聚氨酯或EVA。
8.权利要求1的制品,其中泡沫在至少三面上被不粘附层包围。
9.权利要求1的制品,其中构造不粘附层,以便允许仅仅在一个方向上透过湿气,这一方向为泡沫层的方向。
10.权利要求1的制品,其中不粘附层被穿孔。
11.权利要求1的制品,进一步包括置于至少一部分膜上的粘合剂。
12.权利要求1的制品,其中膜包括约300-3000gm/m2/天的水蒸气透射速度。
13.权利要求1的制品,其中泡沫包括螺旋割纹,当在其内吸收湿气时,促进泡沫的差别溶胀,或其中所述至少一层泡沫层包括在第二泡沫层中的第一泡沫层,当在其内吸收湿气时第一泡沫层具有的溶胀性能不同于第二泡沫层的溶胀性能,结果当在其内吸收湿气时泡沫翘曲或倾斜。
14.一种制品,它包括至少一层泡沫层,该泡沫包括不同大小的孔,至少一些孔至少部分被至少一种可洗脱的抗微生物剂填充,不同大小的孔在泡沫层内形成梯度。
15.权利要求14的制品,包括约0.01%-2%重量抗微生物剂,其中泡沫包括聚氨酯泡沫,藻酸盐(酯)泡沫,透明质酸泡沫,生物玻璃泡沫,或胶原泡沫;和其中抗微生物剂包括聚合的双胍;阳离子季铵化合物;聚合的季铵化合物;聚季铵盐;阳离子抗微生物肽或其组合。
16.权利要求14的制品,其中制品包括伤口敷料,泡沫具有面向伤口的一面,其中梯度包括与面向伤口的一面相邻布置的相对较大的孔,和泡沫内在进一步远离面向伤口一面的相对较小的孔;其中这些孔限定了平均孔度范围为约50-100微米,约10-50微米,和约1-10微米的基本上三峰孔度的分布。
17.权利要求14的制品,其中制品包括伤口敷料,该泡沫具有面向伤口的一面,其中梯度包括与面向伤口的一面相邻布置的相对较小的孔,和泡沫内在进一步远离面向伤口一面的相对较大的孔;其中这些孔限定了平均孔度范围为约50-100微米,约10-50微米,和约1-10微米的基本上三峰孔度的分布。
18.一种制品,它包括泡沫基体和与泡沫基体一起布置的多种可溶解部件,与可溶解部件结合的至少一种抗微生物剂,以便当其溶解时,抗微生物剂被洗脱且在泡沫基体内产生孔或空隙。
19.权利要求18的制品,其中泡沫包括聚氨酯泡沫,藻酸盐(酯)泡沫,透明质酸泡沫,生物玻璃泡沫,或胶原泡沫;其中抗微生物剂包括聚合的双胍;阳离子季铵化合物;聚合的季铵化合物;聚季铵盐;阳离子抗微生物肽或其组合,且其中可溶解的部件包括玻璃珠、淀粉颗粒或藻酸盐(酯)颗粒。
20.权利要求18的制品,进一步包括布置在泡沫基体内的不可溶解的部件。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13633408P | 2008-08-28 | 2008-08-28 | |
US13633508P | 2008-08-28 | 2008-08-28 | |
US61/136,334 | 2008-08-28 | ||
US61/136,335 | 2008-08-28 | ||
PCT/US2009/055149 WO2010025219A1 (en) | 2008-08-28 | 2009-08-27 | Antimicrobial foam compositions, articles and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102170779A true CN102170779A (zh) | 2011-08-31 |
Family
ID=41721908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801390191A Pending CN102170779A (zh) | 2008-08-28 | 2009-08-27 | 抗微生物泡沫组合物,制品和方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20100260824A1 (zh) |
EP (1) | EP2323480A4 (zh) |
CN (1) | CN102170779A (zh) |
AU (2) | AU2009285769B2 (zh) |
WO (1) | WO2010025219A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106999622A (zh) * | 2014-12-04 | 2017-08-01 | 3M创新有限公司 | 包含生物玻璃的抗微生物组合物 |
CN110891617A (zh) * | 2017-07-12 | 2020-03-17 | 史密夫及内修公开有限公司 | 抗微生物或伤口护理材料、装置和用途 |
CN114040785A (zh) * | 2019-05-02 | 2022-02-11 | 国家健康科学研究所 | 具有延长抗微生物活性的透明质酸水凝胶 |
CN115135348A (zh) * | 2020-02-18 | 2022-09-30 | 爱惜康股份有限公司 | 具有梯度密度的熔喷敷料 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011130246A2 (en) * | 2010-04-13 | 2011-10-20 | Kci Licensing, Inc. | Compositions with reactive ingredients, and wound dressings, apparatuses, and methods |
CZ22394U1 (cs) * | 2011-03-11 | 2011-06-20 | Contipro C, A.S. | Antimikrobiální smes a kryt pro podporu hojení ran s antimikrobiálním úcinkem |
US20120310186A1 (en) * | 2011-06-06 | 2012-12-06 | Tyco Healthcare Group Lp | Dressings and Related Methods Therefor |
WO2013032745A1 (en) * | 2011-08-31 | 2013-03-07 | Kci Licensing, Inc. | Reduced-pressure treatment and debridement systems and methods |
GB2501055B (en) * | 2012-02-01 | 2017-08-30 | Banwell Paul | Scar reduction apparatus |
WO2013167671A2 (de) | 2012-05-08 | 2013-11-14 | Nolax Ag | Verfahren zur herstellung einer zwei-komponenten-polyurethanzusammensetzung umfassend ein oder mehrere in polaren lösungsmitteln lösliche additive |
US10179074B2 (en) * | 2012-07-16 | 2019-01-15 | Medline Industries, Inc. | Alginate wound dressing and method of making the same |
GB2543672A (en) * | 2014-08-13 | 2017-04-26 | Essentra Porous Tech Corp | Anti-microbial foams containing polymer-stabilized silver nanoparticles |
EP3522844B1 (en) * | 2016-10-07 | 2022-06-29 | 3M Innovative Properties Company | Conformable wound dressing and delivery system |
GB201711181D0 (en) | 2017-07-12 | 2017-08-23 | Smith & Nephew | Polymer foam material, device and use |
CN108032478B (zh) * | 2017-12-12 | 2022-04-08 | 宁波格林美孚新材料科技有限公司 | 一种不同梯度密度的热塑性聚氨酯发泡制品及其成型工艺 |
JP2022518952A (ja) * | 2019-01-28 | 2022-03-17 | コア サイエンティフィック クリエイションズ リミテッド | 傷手当用品組成物および方法 |
WO2020198649A1 (en) * | 2019-03-28 | 2020-10-01 | Biodaptive Advanced Materials, Llc | Flexible absorbent bandage |
US20230133954A1 (en) * | 2021-11-01 | 2023-05-04 | Medtronic, Inc. | Antimicrobial foam articles |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4541426A (en) * | 1983-04-06 | 1985-09-17 | Smith & Nephew Associated Companies P.L.C. | Dressing |
US5465735A (en) * | 1994-12-01 | 1995-11-14 | The Kendall Company | Wound dressing |
US6333093B1 (en) * | 1997-03-17 | 2001-12-25 | Westaim Biomedical Corp. | Anti-microbial coatings having indicator properties and wound dressings |
US20030097103A1 (en) * | 2001-11-21 | 2003-05-22 | Horney James Cameron | Absorbent article |
US6605751B1 (en) * | 1997-11-14 | 2003-08-12 | Acrymed | Silver-containing compositions, devices and methods for making |
US20070237812A1 (en) * | 2006-04-11 | 2007-10-11 | Tyco Healthcare Group | Multi-layer wound dressings |
CN101252905A (zh) * | 2005-07-15 | 2008-08-27 | 泰科保健集团有限合伙公司 | 伤口敷料和制造及使用其的方法 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4252120A (en) * | 1978-03-23 | 1981-02-24 | Matburn (Holdings) Ltd. | Colostomy seal |
DE2914386A1 (de) * | 1978-04-13 | 1979-10-25 | Andersson A E Bror | Desodorierendes und desinfizierendes, fluessigkeitsaufsaugendes erzeugnis und verfahren zu seiner herstellung |
US4214582A (en) * | 1979-02-07 | 1980-07-29 | The Kendall Company | Surgical dressing |
US4860737A (en) * | 1981-02-13 | 1989-08-29 | Smith And Nephew Associated Companies P.L.C. | Wound dressing, manufacture and use |
US4655210A (en) * | 1986-01-17 | 1987-04-07 | Seton Company | Foam bandage |
US4643181A (en) * | 1986-04-04 | 1987-02-17 | Surgikos, Inc. | Antimicrobial dressing or drape material |
EP0242415B1 (de) * | 1986-04-22 | 1989-01-25 | Karl Otto Braun KG | Textiles Flächengebilde zur Wundversorgung |
GB8620227D0 (en) * | 1986-08-20 | 1986-10-01 | Smith & Nephew Ass | Wound dressing |
US4759354A (en) * | 1986-11-26 | 1988-07-26 | The Kendall Company | Wound dressing |
US4906240A (en) * | 1988-02-01 | 1990-03-06 | Matrix Medica, Inc. | Adhesive-faced porous absorbent sheet and method of making same |
GB8906100D0 (en) * | 1989-03-16 | 1989-04-26 | Smith & Nephew | Laminates |
JP2719671B2 (ja) * | 1989-07-11 | 1998-02-25 | 日本ゼオン株式会社 | 創傷被覆材 |
US5409472A (en) * | 1989-08-03 | 1995-04-25 | Smith & Nephew Plc | Adhesive polymeric foam dressings |
US5833665A (en) * | 1990-06-14 | 1998-11-10 | Integra Lifesciences I, Ltd. | Polyurethane-biopolymer composite |
US5906834A (en) * | 1992-06-15 | 1999-05-25 | The Gillette Company | Color changing matrix as wear indicator |
GB9206509D0 (en) * | 1992-03-25 | 1992-05-06 | Jevco Ltd | Heteromorphic sponges containing active agents |
GB9302970D0 (en) * | 1993-02-15 | 1993-03-31 | Smith & Nephew | Absorbant dressing,manufacture and use |
GB9411429D0 (en) * | 1994-06-08 | 1994-07-27 | Seton Healthcare Group Plc | Wound dressings |
GB9424562D0 (en) * | 1994-12-06 | 1995-01-25 | Giltech Ltd | Product |
DE19503336C2 (de) * | 1995-02-02 | 1998-07-30 | Lohmann Therapie Syst Lts | Arzneiform zur Abgabe von Wirkstoffen an Wunden, Verfahren zu ihrer Herstellung und ihre Verwendung |
GB9510226D0 (en) * | 1995-05-20 | 1995-07-19 | Smith & Nephew | Sterilisable cream or paste product for topical application |
US5968542A (en) * | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
GB2311027B (en) * | 1996-03-15 | 1999-10-27 | Johnson & Johnson Medical | Coated bioabsorbable beads for wound treatment |
US5744150A (en) * | 1997-01-29 | 1998-04-28 | Xomed Surgical Products, Inc. | Softened antimicrobial sponge material with color change indication of antimicrobial activity |
US5718916A (en) * | 1997-02-03 | 1998-02-17 | Scherr; George H. | Alginate foam products |
SE513964C2 (sv) * | 1999-03-01 | 2000-12-04 | Moelnlycke Health Care Ab | Sårförband innefattande ett skikt av ett hydrofilt skum |
US6333029B1 (en) * | 1999-06-30 | 2001-12-25 | Ethicon, Inc. | Porous tissue scaffoldings for the repair of regeneration of tissue |
US6566576B1 (en) * | 2000-01-04 | 2003-05-20 | James F. Komerska | Hydrocolloid foam medical dressings and method of making the same |
US7393522B2 (en) * | 2000-01-12 | 2008-07-01 | Novabay Pharmaceuticals, Inc. | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
US6294948B1 (en) * | 2000-07-06 | 2001-09-25 | Micron Technology, Inc. | Voltage pump with diode for pre-charge |
US20060004314A1 (en) * | 2001-06-14 | 2006-01-05 | Hemcon, Inc. | Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan |
US6787682B2 (en) * | 2001-11-05 | 2004-09-07 | Hollister Incorporated | Absorbent foam wound dressing |
JP4580649B2 (ja) * | 2001-12-21 | 2010-11-17 | アルコン、インコーポレイテッド | ナノ粒子を殺生物剤の担体として眼科用組成物に使用する方法 |
EP1374812A1 (en) * | 2002-06-28 | 2004-01-02 | Biopol Co., Ltd. | Multilayered microporous foam dressing and method for manufacturing the same |
US8100872B2 (en) * | 2002-10-23 | 2012-01-24 | Tyco Healthcare Group Lp | Medical dressing containing antimicrobial agent |
US6838589B2 (en) * | 2003-02-19 | 2005-01-04 | 3M Innovative Properties Company | Conformable wound dressing |
US6974128B2 (en) * | 2003-06-10 | 2005-12-13 | Xerox Corporation | Sheet registration deskew with plural arcuate independently repositionable baffles |
EP1755624A4 (en) * | 2004-05-03 | 2009-04-29 | Neosil Inc | POLYCENTRIC ANTIMICROBIAL THERAPEUTIC |
US20060258969A1 (en) * | 2005-05-12 | 2006-11-16 | Brown Medical Industries | Shower patch |
FR2889649A1 (fr) * | 2005-08-11 | 2007-02-16 | Eastman Kodak Co | Pansement et agent antiseptique contenant de l'argent |
GB2433263A (en) * | 2005-12-15 | 2007-06-20 | Ethicon Inc | Antimicrobial polyurethane foam |
BRPI0707708A2 (pt) * | 2006-02-07 | 2011-05-10 | Tyco Healthcare | curativo de lesço cirérgica |
PL2524705T3 (pl) * | 2011-05-19 | 2014-12-31 | Lohmann & Rauscher Gmbh & Co Kg | Sterylne opatrunki ran zawierające syntetyczny elastomer trój-blokowy i hydrofobowy polimer biguanidyny |
EP2524706B1 (de) * | 2011-05-19 | 2014-07-23 | Lohmann & Rauscher GmbH & Co. KG | Sterile Wundauflage mit einem synthethischen Dreiblock-Elastomer |
-
2009
- 2009-08-27 WO PCT/US2009/055149 patent/WO2010025219A1/en active Application Filing
- 2009-08-27 US US12/548,532 patent/US20100260824A1/en not_active Abandoned
- 2009-08-27 EP EP09810559A patent/EP2323480A4/en not_active Withdrawn
- 2009-08-27 CN CN2009801390191A patent/CN102170779A/zh active Pending
- 2009-08-27 AU AU2009285769A patent/AU2009285769B2/en not_active Ceased
-
2014
- 2014-06-24 AU AU2014203416A patent/AU2014203416B2/en not_active Ceased
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4541426A (en) * | 1983-04-06 | 1985-09-17 | Smith & Nephew Associated Companies P.L.C. | Dressing |
US5465735A (en) * | 1994-12-01 | 1995-11-14 | The Kendall Company | Wound dressing |
US6333093B1 (en) * | 1997-03-17 | 2001-12-25 | Westaim Biomedical Corp. | Anti-microbial coatings having indicator properties and wound dressings |
US6605751B1 (en) * | 1997-11-14 | 2003-08-12 | Acrymed | Silver-containing compositions, devices and methods for making |
US20030097103A1 (en) * | 2001-11-21 | 2003-05-22 | Horney James Cameron | Absorbent article |
CN101252905A (zh) * | 2005-07-15 | 2008-08-27 | 泰科保健集团有限合伙公司 | 伤口敷料和制造及使用其的方法 |
US20070237812A1 (en) * | 2006-04-11 | 2007-10-11 | Tyco Healthcare Group | Multi-layer wound dressings |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106999622A (zh) * | 2014-12-04 | 2017-08-01 | 3M创新有限公司 | 包含生物玻璃的抗微生物组合物 |
CN110891617A (zh) * | 2017-07-12 | 2020-03-17 | 史密夫及内修公开有限公司 | 抗微生物或伤口护理材料、装置和用途 |
CN114040785A (zh) * | 2019-05-02 | 2022-02-11 | 国家健康科学研究所 | 具有延长抗微生物活性的透明质酸水凝胶 |
CN115135348A (zh) * | 2020-02-18 | 2022-09-30 | 爱惜康股份有限公司 | 具有梯度密度的熔喷敷料 |
Also Published As
Publication number | Publication date |
---|---|
EP2323480A4 (en) | 2013-02-27 |
AU2009285769B2 (en) | 2014-05-01 |
WO2010025219A1 (en) | 2010-03-04 |
AU2014203416A1 (en) | 2014-07-10 |
AU2014203416B2 (en) | 2015-11-26 |
WO2010025219A8 (en) | 2011-06-23 |
US20100260824A1 (en) | 2010-10-14 |
EP2323480A1 (en) | 2011-05-25 |
AU2009285769A1 (en) | 2010-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102170779A (zh) | 抗微生物泡沫组合物,制品和方法 | |
EP3651815B1 (en) | Antimicrobial or wound care materials, devices and uses | |
US11167059B2 (en) | Compositions with reactive ingredients, and wound dressings, apparatuses, and methods | |
ES2896175T3 (es) | Espuma compuesta en el tratamiento de heridas | |
US11690933B2 (en) | Absorbent aliphatic polyurethane foam product | |
AU2009265996B9 (en) | Wound dressing | |
KR101433058B1 (ko) | 은 함유 발포체 구조물 | |
EP0097517A1 (en) | Wound dressing, manufacture and use | |
AU2018280743A1 (en) | Foam in wound treatment | |
EP2318207A1 (en) | Anti-microbial fibers and related articles and methods | |
JPH04503763A (ja) | 吸収具とその前駆物 | |
IE52669B1 (en) | Wound dressing,manufacture and use | |
EP0106439A1 (en) | Wound dressing and its manufacture | |
WO2003092754A1 (en) | Ionically crosslinked alginate hydrogels, process for their manufacture and their use in medical devices | |
JPH07508429A (ja) | 創傷用包帯,創傷用被覆物もしくはキャリアマトリックス | |
US20080317829A1 (en) | Method for the Production of a Wound Pad | |
KR102164484B1 (ko) | 키토산으로 표면 코팅된 폴리우레탄 폼 및 이의 제조방법 | |
JP2673456B2 (ja) | 外用貼付剤 | |
EP4041326A1 (en) | Foam patent surfactant | |
KR20210114089A (ko) | 은과 키토산으로 표면 코팅된 폴리우레탄 폼 및 이의 제조방법 | |
PL221886B1 (pl) | Opatrunek przyspieszający ziarninowanie i sposób wytwarzania opatrunku przyspieszającego ziarninowanie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110831 |